Registered title, quoted from ClinicalTrials.gov
Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
An open trial on moyamoya disease, registered on ClinicalTrials.gov. Led by Beijing Tiantan Hospital; 12 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 13
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorBeijing Tiantan Hospital首都医科大学附属北京天坛医院BeijingHospital page
- Study siteChildren's Hospital of Fudan University复旦大学附属儿科医院ShanghaiHospital page
- Study siteChinese PLA General Hospital中国人民解放军总医院BeijingHospital page
- Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
- Study siteFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page
- Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
- Study siteHenan Provincial People's Hospital河南省人民医院ZhengzhouHospital page
- Study siteHuashan Hospital复旦大学附属华山医院ShanghaiHospital page
- Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
- Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
- Study siteWest China Hospital四川大学华西医院ChengduHospital page
- Study siteXuanwu Hospital首都医科大学宣武医院BeijingHospital page
- Study siteZhongnan Hospital of Wuhan University武汉大学中南医院WuhanHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07894107, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 2
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (2 points)Hide the checklist
12 years to 70 years; sex: all
Registered eligibility fields
Pregnancy or breastfeeding.
Exclusion criterion 2
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07894107, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria
- Age 12 to 70 years.
- Diagnosis of moyamoya disease or moyamoya syndrome by DSA, CTA or MRA.
- Ability to complete neurological and cognitive assessments.
- Ability to complete at least 12 months of clinical follow-up and willingness, in principle, to complete 24 months of follow-up.
- At least one analyzable baseline vascular imaging examination in original DICOM format, including CTA, MRA, or DSA.
- Written informed consent provided by the participant and/or legally authorized representative.
Exclusion Criteria
- Refusal to participate or inability to complete follow-up.
- Pregnancy or breastfeeding.
- Coexisting cerebrovascular malformation, intracranial tumor, hydrocephalus, or another disorder that may independently affect stroke or cognitive outcomes.
- Severe visual impairment, aphasia, impaired consciousness, psychiatric illness, or another disorder that prevents valid cognitive assessment, including Alzheimer's disease, Parkinson's disease, or frontotemporal dementia.
- Cardiac conditions that may cause cardioembolic stroke, including atrial fibrillation, patent foramen ovale or other right-to-left shunting cardiac disease, intracardiac mural thrombus, or infective endocarditis; or severe hepatic or renal dysfunction, coagulation disorders, malignancy, or severe cardiopulmonary disease.
- Receipt of an investigational drug or device within 30 days before screening, or current participation in another interventional clinical trial that may interfere with this study.
- Previous cerebral revascularization surgery.
Quoted from ClinicalTrials.gov, NCT07894107, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07894107, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.